blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1113819

EP1113819 - ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT) WITH GLUCURONIDASE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.12.2011
Database last updated on 26.06.2024
Most recent event   Tooltip17.05.2013Lapse of the patent in a contracting state
New state(s): LU		published on 19.06.2013  [2013/25]
Applicant(s)For all designated states
Immunomedics, Inc.
300 American Road
Morris Plains, NJ 07950 / US
[2011/08]
Former [2001/28]For all designated states
Immunomedics, Inc.
300 American Road
Morris Plains, New Jersey 07950 / US
Inventor(s)01 / GRIFFITHS, Gary, L.
36 Edgehill Avenue
Morristown, NJ 07960 / US
02 / HANSEN, Hans, J.
118 Moonraker Drive
Slidell, LA 70458 / US
 [2001/28]
Representative(s)Bohmann, Armin K., et al
Bohmann
Anwaltssozietät
Nymphenburger Strasse 1
80335 München / DE
[N/P]
Former [2008/42]Bohmann, Armin K., et al
Bohmann & Loosen Anwaltssozietät Nymphenburger Strasse 1
80335 München / DE
Former [2007/32]Bohmann, Armin K., et al
Bohmann & Loosen Anwaltssozietät Nymphenburger Strasse 1
80335 München / DE
Former [2001/28]Maschio, Antonio
D Young & Co, 21 New Fetter Lane
London EC4A 1DA / GB
Application number, filing date99948261.517.09.1999
[2001/28]
WO1999US21308
Priority number, dateUS19980101039P18.09.1998         Original published format: US 101039 P
[2001/28]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO0016808
Date:30.03.2000
Language:EN
[2000/13]
Type: A2 Application without search report 
No.:EP1113819
Date:11.07.2001
Language:EN
The application published by WIPO in one of the EPO official languages on 30.03.2000 takes the place of the publication of the European patent application.
[2001/28]
Type: B1 Patent specification 
No.:EP1113819
Date:23.02.2011
Language:EN
[2011/08]
Search report(s)International search report - published on:EP28.09.2000
ClassificationIPC:A61K47/48
[2001/28]
CPC:
B82Y5/00 (EP); A61K47/6899 (EP); A61P35/00 (EP)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2011/08]
Former [2001/28]AT,  BE,  CH,  CY,  DE,  DK,  ES,  FI,  FR,  GB,  GR,  IE,  IT,  LI,  LU,  MC,  NL,  PT,  SE 
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
RONot yet paid
SINot yet paid
TitleGerman:ANTIKÖRPER VERWIESENE ENZYMPRODRUGTHERAPIE MIT GLUKURONIDASE[2001/28]
English:ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT) WITH GLUCURONIDASE[2001/28]
French:PROCEDES ET COMPOSITIONS PERMETTANT D'AUGMENTER LA TOXICITE SPECIFIQUE CIBLE D'UN MEDICAMENT CHIMIOTHERAPIQUE[2001/28]
Entry into regional phase18.04.2001National basic fee paid 
18.04.2001Designation fee(s) paid 
18.04.2001Examination fee paid 
Examination procedure18.03.2000Request for preliminary examination filed
International Preliminary Examining Authority: EP
18.04.2001Examination requested  [2001/28]
04.06.2007Despatch of a communication from the examining division (Time limit: M06)
28.03.2008Reply to a communication from the examining division
08.05.2008Despatch of a communication from the examining division (Time limit: M06)
08.01.2009Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
17.03.2009Reply to a communication from the examining division
16.11.2009Date of oral proceedings
04.12.2009Despatch of a communication from the examining division (Time limit: M02)
04.12.2009Minutes of oral proceedings despatched
15.02.2010Reply to a communication from the examining division
05.08.2010Communication of intention to grant the patent
15.12.2010Fee for grant paid
15.12.2010Fee for publishing/printing paid
Opposition(s)24.11.2011No opposition filed within time limit [2012/05]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
28.03.2008Request for further processing filed
28.03.2008Full payment received (date of receipt of payment)
Request granted
14.04.2008Decision despatched
Fees paidRenewal fee
03.09.2001Renewal fee patent year 03
22.08.2002Renewal fee patent year 04
22.08.2003Renewal fee patent year 05
28.09.2004Renewal fee patent year 06
14.09.2005Renewal fee patent year 07
11.09.2006Renewal fee patent year 08
12.09.2007Renewal fee patent year 09
11.09.2008Renewal fee patent year 10
23.09.2009Renewal fee patent year 11
27.09.2010Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT23.02.2011
BE23.02.2011
CY23.02.2011
DK23.02.2011
FI23.02.2011
IT23.02.2011
NL23.02.2011
SE23.02.2011
GR24.05.2011
ES03.06.2011
PT23.06.2011
IE17.09.2011
LU17.09.2011
CH30.09.2011
LI30.09.2011
MC30.09.2011
[2013/25]
Former [2012/35]AT23.02.2011
BE23.02.2011
CY23.02.2011
DK23.02.2011
FI23.02.2011
IT23.02.2011
NL23.02.2011
SE23.02.2011
GR24.05.2011
ES03.06.2011
PT23.06.2011
IE17.09.2011
CH30.09.2011
LI30.09.2011
MC30.09.2011
Former [2012/33]AT23.02.2011
BE23.02.2011
CY23.02.2011
DK23.02.2011
FI23.02.2011
IT23.02.2011
NL23.02.2011
SE23.02.2011
GR24.05.2011
ES03.06.2011
PT23.06.2011
CH30.09.2011
LI30.09.2011
MC30.09.2011
Former [2012/23]AT23.02.2011
BE23.02.2011
CY23.02.2011
DK23.02.2011
FI23.02.2011
IT23.02.2011
NL23.02.2011
SE23.02.2011
GR24.05.2011
ES03.06.2011
PT23.06.2011
MC30.09.2011
Former [2012/20]AT23.02.2011
BE23.02.2011
CY23.02.2011
DK23.02.2011
FI23.02.2011
NL23.02.2011
SE23.02.2011
GR24.05.2011
ES03.06.2011
PT23.06.2011
MC30.09.2011
Former [2011/47]AT23.02.2011
BE23.02.2011
CY23.02.2011
DK23.02.2011
FI23.02.2011
NL23.02.2011
SE23.02.2011
GR24.05.2011
ES03.06.2011
PT23.06.2011
Former [2011/39]AT23.02.2011
BE23.02.2011
CY23.02.2011
FI23.02.2011
NL23.02.2011
SE23.02.2011
GR24.05.2011
ES03.06.2011
PT23.06.2011
Former [2011/37]BE23.02.2011
CY23.02.2011
FI23.02.2011
SE23.02.2011
GR24.05.2011
ES03.06.2011
PT23.06.2011
Former [2011/36]SE23.02.2011
GR24.05.2011
ES03.06.2011
PT23.06.2011
Cited inInternational search[A]WO9109134  (TAKEDA CHEMICAL INDUSTRIES LTD [JP]) [A] 1-6,10-23* abstract *;
 [X]EP0501215  (BEHRINGWERKE AG [DE]) [X] 1-6,10-23 * abstract *;
 [X]WO9620011  (ZENECA LTD [GB], et al) [X] 1-6,10-23 * example 22; claim 8 *;
 [X]WO9741898  (IMMUNOMEDICS INC [US], et al) [X] 1-6,10-23 * abstract * * see embodiment 16; page 23, lines 32-40 *;
 [XP]US5851527  (HANSEN HANS JOHN [US]) [XP] 1-6,10-23 * column 7, lines 40-55; claims 19-21 *;
 [PX]WO9942593  (ST JUDE CHILDRENS RES HOSPITAL [US], et al) [PX] 1-6,10-23 * abstract * * page 23, lines 7-15 *;
 [E]WO9966951  (IMMUNOMEDICS INC [US], et al) [E] 1-6,10-23 * pages 29-32; claims 1,2,30,31 *;
 [XP]  - LEU Y L ET AL, "Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy ( ADEPT ).", JOURNAL OF MEDICINAL CHEMISTRY, (1999 SEP 9) 42 (18) 3623-8., XP000867705 [XP] 1-6,10-23 * formula 3; page 3623, column 1 * * page 3625, column 2, paragraph 2 *

DOI:   http://dx.doi.org/10.1021/jm990124q
 [XP]  - DANKS M K ET AL, "Comparison of activation of CPT - 11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.", CLINICAL CANCER RESEARCH, (1999 APR) 5 (4) 917-24., XP000867715 [XP] 1-6,10-23 * abstract * * page 917, column 2, paragraph 2 * * page 922, column 1 *
 [X]  - TAKAYAMA H ET AL, "Synthesis of a new class of camptothecin derivatives, the long-chain fatty acid esters of 10-hydroxycamptothecin, as a potent prodrug candidate, and their in vitro metabolic conversion by carboxylesterases", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, (19980303), vol. 8, no. 5, ISSN 0960-894X, pages 415 - 418, XP004136875 [X] 1-5 * abstract *

DOI:   http://dx.doi.org/10.1016/S0960-894X(98)00039-0
 [X]  - MELTON ET AL, "Antibody-directed enzyme prodrug therapy (ADEPT). Review article", DRUGS OF THE FUTURE,ES,BARCELONA, (19960101), vol. 21, no. 2, ISSN 0377-8282, pages 167 - 181, XP002080157 [X] 1-6,10-23 * pages 173-174; table 1 *
 [X]  - HAY M.P. ET AL, "Antibody-directed enzyme-prodrug therapy ( ADEPT ).", DRUGS OF THE FUTURE, (1996) 21/9 (917-931)., XP000874404 [X] 1-6,10-23 * abstract * * page 925 * * page 928 *
Examination   - ROFFLER ET AL, "Anti-neoplastic glucoronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate", BIOCHEM. PHARMACOL., (19911231), vol. 42, page 2062, XP000874496

DOI:   http://dx.doi.org/10.1016/0006-2952(91)90612-9
    - HAISMA ET AL, "A monoclonal antibody-b-glucuronide conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer", vol. 66, page 474, XP000882039
by applicantWO9741898
    - ROFFLER ET AL., BIOCHEM PHARMACOL., vol. 42, pages 2062 - 2065
    - HAISMA ET AL., BR. J. CANCER, (1992), vol. 66, pages 474 - 478
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.